In trial NCT04576494, adults with genetic SMA type 2 and type 3 were enrolled to study the functional effect of Nusinersen (Spinraza), an ASO designed to allow the SMN2 gene to produce the full-length and functionally normal protein. Here, SMN2 is linked to spinal muscular atrophy, type II.